Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 42

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 42
---
, Herzliya Pituach, 46140 Israel. (3) The information shown is based solely upon disclosures filed on a Schedule 13G/A filed on January 26, 2024 by BlackRock, Inc. The address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055. (4) Consists of (i) 302,223 shares of common stock held by Dr. Seehra and (ii) 1,415,746 shares issuable upon the exercise of options granted to Dr. Seehra that are exercisable within 60 days of April 11, 2025. (5) Dr. Cooper resigned as Chief Medical Officer effective March 12, 2024. (6) Consists of shares issuable upon the exercise of options granted to Mr. Regnante that are exercisable within 60 days of April 11, 2025. (7) Consists of shares issuable upon the exercise of options granted to Mr. Rovaldi that are exercisable within 60 days of April 11, 2025. (8) Consists of (i) 200 shares of common stock held by Mr. Bienaimé and (ii) 5,866 shares issuable upon the exercise of options granted to Mr. Bienaimé that are exercisable within 60 days of April 11, 2025. (9) Consists of shares issuable upon the exercise of options granted to Mr. Farzan that are exercisable within 60 days of April 11, 2025. 27 TABLE OF CONTENTS (10) The information shown is based, in part, upon disclosures filed on a Schedule 13D/A filed on December 13, 2023 by (i) OrbiMed Advisors LLC (“ OrbiMed Advisors ”), (ii) OrbiMed Capital GP VII LLC (“ OrbiMed GP VII ”), (iii), OrbiMed Genesis GP LLC (“ Genesis GP ”) and (iv) OrbiMed Capital LLC (“ OrbiMed Capital ”). Consists of (i) 899,212 shares of common stock held by OrbiMed Private Investments VII, LP (“ OPI VII ”), (ii) 119,522 shares of common stock held by OrbiMed Genesis Master Fund, L.P. (“ Genesis ”) and (iii) 36,586 shares issuable upon the exercise of options granted to Dr. Gordon